Blog
RSS FeedPosted by Michael Wonder on 16 May 2025
ICER publishes final evidence report on treatment for retinitis pigmentosa
15 May 2025 - Independent appraisal committee voted that current evidence is adequate to demonstrate a net health benefit of ...
Posted by Michael Wonder on 29 Apr 2025
Institute for Clinical and Economic Review to assess treatments for obesity management
29 April 2025 - Report will be subject of New England CEPAC meeting in November 2025; draft scoping document open ...
Posted by Michael Wonder on 15 Apr 2025
ICER releases draft evidence report on treatment for secondary progressive multiple sclerosis
15 April 2025 - Public comment period now open until 13 May 2025; Requests to make oral comment during public ...
Posted by Michael Wonder on 10 Apr 2025
ICER releases obesity medications white paper examining strategies to ensure affordable access
9 April 2025 - Paper analyses policy reforms and market actions to achieve affordable and equitable access for GLP-1 obesity ...
Posted by Michael Wonder on 01 Apr 2025
ICER publishes final evidence report on treatment for acute pain
31 March 2025 - Independent appraisal committee vote was split on the net health benefit of suzetrigine compared to non-systemic ...
Posted by Michael Wonder on 27 Mar 2025
ICER publishes evidence report on treatment for retinitis pigmentosa
26 March 2025 - There are significant uncertainties regarding long term efficacy and durability of sonpiretigene isteparvovec; ICER estimates that ...
Posted by Michael Wonder on 20 Mar 2025
Health Economics Methods Advisory Group selects first area for study: assessing treatment benefits appropriate to consider in HTA decision-making
18 March 2025 - The US based ICER, England’s NICE and Canada’s Drug Agency have selected the first research topic ...
Posted by Michael Wonder on 11 Mar 2025
ICER to assess treatment for non-cystic fibrosis bronchiectasis
11 March 2025 - Report will be subject of CTAF meeting in September 2025; draft scoping document open to public ...
Posted by Michael Wonder on 04 Mar 2025
ICER publishes special report on COPD therapies as part of CMS public comment process on Medicare drug price negotiations
3 March 2025 - Report reflects legislative specifications in the Inflation Reduction Act and subsequent CMS guidance. ...
Posted by Michael Wonder on 10 Feb 2025
ICER releases draft evidence report on treatment for advanced retinitis pigmentosa
6 February 2025 - Public comment period now open until 6 March 2025; requests to make oral comment during public ...
Posted by Michael Wonder on 10 Feb 2025
ICER publishes evidence report on treatment for acute pain
5 February 2025 - Current evidence suggests that suzetrigine may provide a net health benefit when compared to no systemic ...
Posted by Michael Wonder on 23 Jan 2025
ICER announces new annual launch price and access report for 2025
22 January 2025 - New report will highlight opportunities to improve affordability and access, and demonstrate the importance of having ...
Posted by Michael Wonder on 07 Jan 2025
ICER to assess treatments for spinal muscular atrophy
6 January 2025 - Report will be subject of Midwest CEPAC meeting in August 2025; draft scoping document open to ...
Posted by Michael Wonder on 20 Dec 2024
ICER publishes fourth annual assessment of barriers to fair access within US commercial insurance prescription drug coverage
19 December 2024 - Most payers evaluated offer fair access across the domains reviewed; findings underscore the need for greater ...
Posted by Michael Wonder on 17 Dec 2024
ICER publishes final evidence report on treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease
16 December 2024 - Independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for ...